skip to Main Content

BIO Investor Conference: New Technologies, Old Pricing Systems, And Insurance Payers In The US

NEW YORK — At a recent biotechnology investors event in the United States, the prospect of repeal or redesign of the Affordable Care Act, the president’s recent remarks on the prospect of Medicare negotiating prices directly with pharmaceutical corporations, and the public debate surrounding high priced medicines, meant few panels were immune from questions of affordability, access and payment.
Go to Source
Author: Kim Treanor

Back To Top